

This is the author-created version of the following work:

Rajiah, Kingston, Maharajan, Mari Kannan, Yeen, Si Jen, and Lew, Sara (2017)
Quality of Life and Caregivers' Burden of Parkinson's Disease.
Neuroepidemiology, 48 (3-4) pp. 131-137.

Access to this file is available from:

<https://researchonline.jcu.edu.au/90395/>

© 2017 S. Karger AG, Basel.

Please refer to the original source for the final version of this work:

<https://doi.org/10.1159/000479031>

1 **Quality of life and caregivers' burden of Parkinson's disease**

2 Kingston Rajiah^a, Mari Kannan Maharajan^a, Si Jen Yeen^a, Sara Lew^b

3 ^a Department of Pharmacy Practice, School of Pharmacy, International Medical University,
4 Kuala Lumpur, Malaysia.

5 ^b President, Malaysian Parkinson's disease Association, Kuala Lumpur, Malaysia.

6

7 **Short title:** Parkinson's disease patients and their care givers

8 *** Address for correspondence:**

9 Kingston Rajiah

10 Lecturer,

11 Pharmacy practice

12 International medical university

13 No. 126, Jalan Jalil Perkasa 19, Bukit Jalil, 57000 Kuala Lumpur, Malaysia

14 Tel: 60146400547

15

16 E-mail:kingrajiah@gmail.com

17 Number of Tables: 5

18 Number of figures: 0

19

20 **Quality of life and caregivers' burden of Parkinson's disease**

21 **Abstract:**

22 **Aim**

23 This study focused on the impact of the clinical features on the QoL of PD patients, and of their
24 caregivers.

25 **Methods**

26 This study included PD patients along with their caregivers, and was undertaken at the
27 Malaysian Parkinson's Disease Association from June 2016 to November 2016. Clinical
28 features of PD patients were assessed using the Movement Disorder Society revised Unified
29 Parkinson Disease Rating Scale (MDS-UPDRS); the Hoehn and Yahr stage and the Schwab
30 and England Activities of Daily Living Scale were used to assess the severity and the ability
31 of Parkinson's disease patients respectively. QoL of PD patients was measured using the
32 Parkinson's Disease Questionnaire-39 (PDQ-39). The revised version of the Zarit Burden
33 Interview assessed caregiver burden.

34 **Results**

35 At least one of the clinical features affected PD patients' QoL, and at least one of the QoL
36 domains affected the caregivers' burden. Clinical features 'Saliva and Drooling', and
37 'Dyskinesia' explained 29% of variance in QoL of PD patients. The QoL domains 'stigma',
38 along with 'emotional wellbeing' explained 48.6% of variance in caregivers' burden.

39 **Conclusions**

The clinical features ‘saliva and drooling’ and ‘dyskinesia’ impacted the QoL of PD patients and the QoL domains ‘stigma’ and ‘emotional wellbeing’ of PD patients impacted their caregivers’ burden.

Keywords: Carers; Malaysia; Quality of life; Clinical features; correlations.

Introduction

Parkinson’s disease (PD) is a progressive neurodegenerative disorder with evolving layers of complexity [1]. Both motor and non-motor symptoms of PD may affect patients’ quality of life (QoL) [2, 3]. Recent developments in the diagnosis and advanced management of PD have increased the patients’ life expectancy towards that to the healthy individuals [4]. Therefore, improvement of the QoL is a significant part of therapeutic plans.

Patients with PD, especially those who are in advanced stages, are in great need of assistance, mostly from their family members or caregivers in terms of medical, emotional, and social support [5]. The role of a caregiver becomes increasingly important with the progression of PD, the severity of motor impairment and increasing age of the patient. The nature and symptoms associated with PD can place significant stresses on the caregivers’ burden. As the prevalence of PD is estimated to more than double by 2030 [6], it is important to recognize and alleviate the burden experienced by caregivers [7].

Many studies conducted on QoL of PD patients were based on the effects of ‘non-motor aspects’ and ‘motor aspects’ [1-3]. Few studies have reported the ‘motor examination’ and ‘complications’ that affect the QoL in PD patients. However, no study has yet been undertaken to include all these aspects (clinical features) together to determine their influence on QoL of PD patients. Similarly, there are no studies on the aspect of PD patients’ QoL which impact on their caregivers’ burden.

In the present study, we examined the impact of clinical features (motor aspect, non-motor aspect, ‘motor examination’ and ‘complications’) on PD patients’ QoL, and the impact of PD patients’ QoL on their caregivers’ burden.

Methods

Study Population and duration

We conducted this study at the Malaysian Parkinson's Disease Association from June 2016 to November 2016. The study included PD patients who have caregivers. Both the patients and caregivers were required to be aged 18 years or above. PD patients who did not have caregivers, and those who were not interested in this study were excluded.

Study design and study participants

This cross-sectional study was done using a convenience sampling method. Each participant gave written, informed consent in accordance with the ethical approval of Joint Committee for Ethics and Research (BP I-1-13 (13) 2016). All the participants were informed about the anonymity and confidentiality of the recorded responses. Out of 153 PD patients invited, 135 PD patients participated in this study along with their caregivers. Sample size was calculated using Raosoft software, a required sample size of 110 was demonstrated; power 80%, distribution of response 50%, with 95% confidence interval and 5% margin of error.

Clinical features assessment of PD patients

Clinical features of PD patients were assessed using the scale the Movement Disorder Society revised Unified Parkinson Disease Rating Scale (MDS-UPDRS) [8]; Hoehn and Yahr stage [9] and Schwab and England Activities of Daily Living Scale [10] were used to assess the severity and the ability of Parkinson’s disease patients respectively. A prior permission from the

Movement Disorder Society was a prerequisite and it was obtained through email communication.

Parkinson's disease Questionnaire (PDQ-39) to measure quality of life

QoL of PD patients was measured using the Parkinson's Disease Questionnaire-39 (PDQ-39), which consists of 39 items within the following eight domains: *mobility, activities of daily living, emotional well-being, stigma, social support, cognition, communication, and bodily discomfort*. The scores on the PDQ-39 range from 0 (never have difficulty) to 100 (always have difficulty), with higher scores reflecting poorer QoL [11]. The domain score = sum of scores of each item in the domain divided by the maximum possible score of all the items in the domain, multiplied by 100. Lower scores reflect better QoL.

Zarit Burden Interview scale (ZBI) to measure caregivers' burden

The revised version of the Zarit Burden Interview [12] was used to assess caregiver burden. All 22 items on the ZBI are rated on a 5-point scale from 0 (*not at all*) to 4 (*extremely*), and a higher ZBI score indicates a higher level of caregiver burden.

Reliability Validity and of the questionnaire

All the questionnaire underwent internal consistency (reliability) and content validity prior to its administration to a small group of 10 samples for a pilot study. For the final analysis, the data of the pilot study were not used.

Data collection procedure

In Malaysian Parkinson's Disease Association, people with Parkinson along with their care givers meet every week. During this period, our researchers approached the people with Parkinson individually in a separate room. Standard questionnaires were used to evaluate the clinical features and quality of life of the people with Parkinson. Self-administered caregiver

burden scale was used on the care givers of separately. All the respondents were evaluated by a research professional who is specialised in Parkinson's disease using UPDRS scale, Modified Hoehn and Yahr Scale and Schwab and England activities of daily living scale. PDQ-39 scale was filled by the respondents. The questionnaire administrated was in English. However, those who had difficulty to fill and understand due to any clinical issue and/or language barrier, the questionnaire were helped by the researchers by getting the response from respondents.

Statistical Analysis

The Statistical Package for Social Science (SPSS) software "version 21" was used for data analysis. Demographic details of the patients and care givers were presented in frequency, percentages and mean with standard deviation. Nonparametric tests was used as the data did not meet the normal distribution as the data collected was convenience sampling method. The UPDRS, PDQ-39 and ZBI scales were calculated according to the standard scoring algorithms. The Mann-Whitney test was used to determine the significance of differences in QoL (PDQ-39 summary index scores) between PD patients who have certain clinical features and those who have not, as determined by UPDRS scores. Spearman rank correlation coefficients were calculated to assess the direction and magnitude of correlation between the clinical features of the PD patients and the QoL. Similarly, the Mann-Whitney test was used to determine the significance of differences in caregivers' burden (ZBI scores) between PD patients' QoL domains which were poor and those domains which were not, as determined by PDQ-39 domains scores. Spearman rank correlation coefficients were calculated to assess the direction and magnitude of correlation between the PDQ-39 domains and the caregivers' burden. Stepwise multiple logistic regression analysis was undertaken to determine the factors that best accounted for variance in QoL and caregivers' burden. Statistical significance was accepted at $p < 0.05$.

Results

122 out of 135 PD patients responded completely to the questionnaire, giving a 90% response rate. There were no incomplete data. Baseline characteristics of the study population are shown in Table 1. The respondents' mean age was 58.1 ± 5.2 years, 56.5% of them were men, and the mean disease duration was 10.6 ± 8.4 years. The overall mean scores for the UPDRS scale indicates that, on average, the respondents' clinical features were from mild to moderate range. Based on the Hoehn and Yahr Scale, about 60% (n=74) of the respondents were in stage 2 (bilateral involvement without impairment of balance) and stage 2.5 (mild bilateral disease with recovery on pull test).

Schwab and England activities of daily living scale rating showed that 61% (n=75) of the respondents were "not completely independent" and 20% (n=25) of the respondents showed "some dependency" (Table 1).

130 caregivers responded completely to the questionnaire out of 135 caregivers (96% response rate). There were no incomplete data. All caregivers were close relatives of the respondents, and most were providing full-time care, with a mean duration of caregiving of 7.2 years. About 70% (n=88) of the care givers experienced moderate to severe burden. The characteristics of the caregivers are given in table 2.

Respondents with clinical features (non-motor aspects) such as 'hallucinations and psychosis', 'depressed mood', and 'urinary problems' had significantly different PDQ-39 summary index scores compared to the respondents who did not have these features (Table 3). However, other clinical features (non-motor aspects) such as; 'features of dopamine dysregulation syndrome' 'anxious mood', 'cognitive impairment', 'sleep problems', 'apathy', 'constipation problems', 'fatigue', 'daytime sleepiness', 'pain and other sensations' and 'light headedness on standing'

155 did not show any significant difference in QoL (PDQ-39 summary index scores), although
156 some of the respondents had these clinical features.

157 In the same way, respondents with clinical features (motor aspects) such as ‘saliva and
158 drooling’, ‘walking and balance’, ‘dressing’ and ‘getting out of bed/ car/ a deep chair’ had
159 significantly different PDQ-39 summary index scores compared to the respondents who did
160 not have these features (Table 3). However, other clinical features (motor aspects) such as
161 ‘eating tasks’, ‘speech’, ‘tremor’, ‘hygiene’, ‘chewing and swallowing’, ‘doing hobbies’,
162 ‘turning in bed’, ‘freezing’ and ‘handwriting’ did not show any significant difference in QoL
163 (PDQ-39 summary index scores), although some of the respondents had these clinical features.
164 Among the motor examination and complications, ‘gait’ and ‘dyskinesia’ had significantly
165 different PDQ-39 summary index scores (Table 3). Also, there was no difference in PDQ-39
166 summary index scores with respect to respondents’ age, gender and duration of disease.

167 Respondents’ PDQ-39 domains scores for ‘activities of daily living’, ‘mobility’, ‘emotional
168 wellbeing’, and ‘stigma’ showed significant difference in caregivers’ ZBI scores (Table 4).
169 However, other PDQ-39 domains scores such as ‘communication and bodily discomfort’,
170 ‘cognition’, and ‘social support’ did not show significant differences in caregivers’ ZBI scores.
171 Also, there was no significant difference in caregivers’ burden scores with respect to
172 caregivers’ age, gender and years dedicated as caregiver, and the number of days providing
173 care in a week.

174 All the clinical features that showed significant difference in the QoL, overall UPDRS scores,
175 PDQ-39 scores and ZBI scores were included in the Spearman correlation analysis (Table 5).
176 The UPDRS scores were significantly and positively correlated with the PDQ-39 scores ($r =$
177 0.68 , $p = 0.004$). This indicates, unsurprisingly, that as the clinical features of disability
178 increase the QoL of the respondents becomes worsen. The clinical feature of ‘hallucinations

and psychosis' positively correlated with the PDQ-39 domains 'stigma' ($r = 0.62, p = 0.02$) and 'emotional wellbeing' ($r = 0.52, p = 0.04$). The clinical feature 'saliva and drooling' was also significantly and positively correlated with PDQ-39 domains 'stigma' ($r = 0.60, p = 0.03$) and 'emotional wellbeing' ($r = 0.58, p = 0.04$). The clinical feature 'gait' was significantly and positively correlated with another clinical feature 'dyskinesia' ($r = 0.41, p = 0.05$); this indicates multicollinearity. The clinical feature 'dyskinesia' was significantly and positively correlated with PDQ-39 domains 'stigma' ($r = 0.52, p = 0.04$) and 'emotional wellbeing' ($r = 0.50, p = 0.05$). Other clinical features such as; 'depressed mood', 'urinary problems', 'walking and balance', 'dressing', 'getting out of bed, a car, or a deep chair' did not show any correlations.

There was a significant positive correlation between the PDQ-39 scores and the ZBI score ($r = 0.76, p = 0.003$). This indicates that, as the QoL of respondents gets worsen the caregivers' burden also get worsen. There was a significant positive correlation between the PDQ-39 domain 'stigma' and the 'ZBI score' ($r = 0.63, p = 0.01$). Also, there was a significant positive correlation between the PDQ-39 domain 'emotional wellbeing' and the 'ZBI score' ($r = 0.58, p = 0.03$). Other PDQ-39 domains such as; 'mobility' and 'activities of daily living' did not show any correlations.

To determine which clinical features contributed to impair the QoL, stepwise linear regression was performed by including all factors that had correlations with QoL scores (Table 5).

Before conducting multiple regressions, the correlations among the predictor variables should be checked. Since there was a correlation between clinical features 'gait', and 'dyskinesia' ($r = 0.41, p = 0.05$), multicollinearity was considered. Hence a separate linear regression analysis was performed for 'gait' and 'dyskinesia' against PDQ-39 summary index score. As a result, the 'gait' F value was too low and p value was not significant ($F(1, 135) = 15.81, R^2 = 0.137, p = 0.41$) whereas for 'dyskinesia', the F value ($1, 135$) = 35.26, with a $R^2 = 0.437$, and $p =$

0.03. Since the p value was significant, 'dyskinesia' was included in the multiple regression and 'gait' was excluded.

After running the multiple regression analysis, the best model was taken into account. Thus, model 2, with the clinical features such as 'saliva and drooling', and 'dyskinesia' explained 29% of variance in QoL scores ($F(3, 135) = 55.48, R^2 = 0.292, p=0.005$). The non-significant contributor 'hallucinations and psychosis' was excluded automatically by the SPSS software.

To determine which PDQ-39 domains contributed to the burden of caregivers, stepwise linear regression was performed by including all factors that were shown to have a correlation (Table 5). Only two factors (stigma and emotional wellbeing) significantly affected the caregivers' burden. In model 1, the 'stigma' variable explained 42.2% of the caregivers' increased burden ($F(1, 130) = 75.92, R^2 = 0.422, p= 0.005$). In model 2, 'stigma' along with 'emotional wellbeing' were the significant predictors with $F(2,130) = 80.43, R^2 = 0.486, p = 0.001$ (48.6% explained variance). Since the model 2 R^2 value was higher than that of model 1, model 2 was selected in this study, with model 2 showing an additional 6.4% of variance explained by the 'emotional wellbeing' variable in relation to the caregivers' burden.

Discussion

As this study had a high response rate, the results may be generalised to a wider population of people with PD and caregivers. Our study revealed that at least one of the clinical features in 'non-motor aspects', 'motor aspects', 'motor examination' and 'complications' has impacted the QoL of PD patients. The non-motor aspects such as 'hallucinations and psychosis', 'depressed mood', and 'urinary problems' had also significantly affected the QoL. Chronic exposure to dopaminergic medication is one of the main causes of hallucinations and psychosis [13]. Depression in PD is multifactorial, with possible contributions from dysfunctions in dopaminergic, serotonergic and noradrenergic systems [14]. Urinary dysfunction, which is a

manifestation of autonomic failure, is common in PD patients and significantly impacts on an individual's QoL [15].

Concerning motor aspects, 'saliva and drooling', 'walking and balance', 'dressing' and 'getting out of bed/car/a deep chair' significantly affected the QoL. Drooling causes psychosocial consequences and affects patient's QoL [16]. The loss of dopaminergic neurons from the substantia nigra pars compacta affects the walking ability and balance [17]. PD patients perceive that they need help from others at some time to even to manage their daily living activities; this contributes to the loss of independence [18]. Gait abnormalities and dyskinesia in PD patients may occur due to dopamine drug on-off fluctuations and this has a direct effect on their QoL [19, 20].

The PDQ-39 QoL domains such as 'mobility', 'activities of daily living', 'emotional wellbeing' and 'stigma' impacted on the caregivers' burden and this is supported by other published literature. Mobility impairment, as well as activities of daily living, have been reported as a burden for caregivers [21]. Increasing disabilities in PD construct a stigma that can lead to social isolation and emotional distress, which, in turn, causes burden to caregivers [22].

Our results revealed that the clinical feature 'hallucinations and psychosis' significantly correlated with the QoL domains 'stigma' and 'emotional wellbeing'. These two QoL domains directly reflect the society, family members and environment where they live. PD patients with hallucinations and psychosis are stigmatised and emotionally affected, and they choose not to tell anyone about these, because they are afraid of being perceived as cognitively incompetent. [22, 23]. The clinical feature 'saliva and drooling' significantly correlated with the QoL domains 'stigma' and 'emotional wellbeing'. 'Saliva and drooling' constitutes one of the most bothersome and troubling problems, often causing stigmatisation and affecting emotional

wellbeing of the people with PD, leading to social embarrassment and isolation [24]. Another clinical feature ‘dyskinesia’ significantly correlated with the QoL domains ‘stigma’ and ‘emotional wellbeing’. Dyskinesia decreases the QoL in PD patients by affecting their emotional health because of stigmatisation [25].

PDQ-39 QoL domains ‘stigma’ and ‘emotional wellbeing’ were significantly correlated with the caregivers’ burden. Stigma experienced by the PD patients affects their caregivers. Stigma and emotional wellbeing may lead to social elimination [22].

Multiple regression analysis revealed that clinical features ‘saliva and drooling’, and ‘dyskinesia’ are the significant contributors that impact on the QoL of PD patients. Psychosocially, drooling in PD patients is one of the primary reasons for poor QoL, emotional distress and social embarrassment [26]. Besides this, PD patients with drooling problems increased their caregivers’ burden [27]. This clearly indicates that ‘sialorrhoea’ in PD patients affects their QoL which in turn reflects on their care givers’ burden. On the other hand, the impact of dyskinesia as a key factor on QoL in PD patients has not been fully elucidated. Sitek (2011) explained the relationship between dyskinesia and ‘stigmatization’ which may impact the QoL of PD patients [28]. ‘Stigma’ and ‘emotional wellbeing’ are the significant contributors that impact the caregivers’ burden. Stigma is a unique contributor that impacts on caregivers’ burden. [29, 30].

Limitations

The QoL in PD patients may also be altered by many factors other than clinical features which are not captured in this study. Though the caregivers’ burden was measured, the QoL of caregivers was not studied.

Conclusions

274 The QoL in PD patients is determined by at least one of the clinical features in ‘non-motor
275 aspects’, ‘motor aspects’ ‘motor examination’ and ‘complications’. The clinical features ‘saliva
276 and drooling’ and ‘dyskinesia’ have significantly impacted the QoL of PD patients. The
277 caregivers’ burden is determined by at least one of the QoL domains. The QoL domains
278 ‘stigma’ and ‘emotional wellbeing’ significantly impacted the caregivers’ burden.

279 **Conflicts of interest:** The authors have no conflict of interest to report.

280 **Disclosure:** All authors have approved the final article.

281 **Authorship**

- 282 1. the conception and design of the study, or acquisition of data, or analysis and
283 interpretation of data: KIR, SJY
- 284 2. drafting the article or revising it critically for important intellectual content: KIR,
285 MMK, SL
- 286 3. final approval of the version to be submitted: KIR, MMK

287 **Funding source:** This work was supported by the Institute for Research, Development &
288 Innovation, International Medical University, Malaysia [grant numbers: BP I-1-13 (13) 2016]

289

291 **References**

- 292 1. Kalia, L.V., Lang, A.E. Parkinson's disease, *The Lancet*. 2015; 386: 896–912.
293 doi:10.1016/s0140-6736(14)61393-3.
- 294 2. Fernandez, H. H. Nonmotor complications of Parkinson disease. *Cleveland Clinic*
295 *Journal of Medicine*. 2012; 79(Suppl_2). doi:10.3949/ccjm.79.s2a.03.
- 296 3. Rahman, S., Griffin, H. J., Quinn, N. P., Jahanshahi, M. Quality of life in Parkinson's
297 disease: The relative importance of the symptoms. *Movement Disorders*. 2008; 23(10):
298 1428-1434. doi:10.1002/mds.21667.
- 299 4. Sato K, Hatano T, Yamashiro K, Kagohashi M, Nishioka K, Izawa N, Mochizuki H,
300 Hattori N, Mori H, Mizuno Y, Juntendo. Parkinson Study Group. Prognosis of
301 Parkinson's disease: Time to stage III, IV, V, and to motor fluctuations, *Movement*
302 *Disorders*. 2006; 21:1384–1395. doi:10.1002/mds.20993.
- 303 5. Greenwell, K., Gray, W. K., Wersch, A. V., Schaik, P. V., & Walker, R. Predictors of
304 the psychosocial impact of being a carer of people living with Parkinson's disease: A
305 systematic review. *Parkinsonism & Related Disorders*. 2015; 21(1): 1-11.
306 doi:10.1016/j.parkreldis.2014.10.013.
- 307 6. Calabrese, V. P., Dorsey, E., Constantinescu, R., Thompson, J., Biglan, K., Holloway,
308 R., Tanner, C. Projected Number of People With Parkinson Disease In The Most
309 Populous Nations, 2005 Through 2030. *Neurology*. 2007; 69(2): 223-224.
310 doi:10.1212/01.wnl.0000271777.50910.73.
- 311 7. Grun, D., Pieri, V., Vaillant, M., & Diederich, N. J. Contributory Factors to Caregiver
312 Burden in Parkinson Disease. *Journal of the American Medical Directors Association*.
313 2016; 17(7): 626-632. doi:10.1016/j.jamda.2016.03.004.

8. Goetz, C. Unified Parkinson's Disease Rating Scale (UPDRS) and The Movement-Disorder Society Sponsored-unified Parkinson's disease Rating Scale (MDS-UPDRS). Encyclopedia of Movement Disorders. 2010; 307-309. doi:10.1016/b978-0-12-374105-9.00091-5.
9. Poewe, W. Global Scales to Stage Disability in PD: The Hoehn and Yahr Scale. Rating Scales in Parkinson's Disease. 2012; 115-122. doi:10.1093/med/9780199783106.003.0258.
10. Siderowf, A. Schwab and England Activities of Daily Living Scale. Encyclopedia of Movement Disorders. 2010; 99-100. doi:10.1016/b978-0-12-374105-9.00070-8.
11. Jenkinson, C., Fitzpatrick, R., Peto, V., Greenhall, R., Hyman, N. The Parkinson's Disease Questionnaire (PDQ-39): development and validation of a Parkinson's disease summary index score. Age and Ageing. (1997; 26(5): 353-357. doi:10.1093/ageing/26.5.353.
12. Yiengprugsawan, V. Caregiver Burden Scale: Zarit interview. Encyclopedia of Quality of Life and Well-Being Research. 2014; 566-567. doi:10.1007/978-94-007-0753-5_281.
13. Rabey, J. M. Hallucinations and psychosis in Parkinson's disease. Parkinsonism and Related Disorders. 2009; 15. doi:10.1016/s1353-8020(09)70846-6.
14. Karbozova, K. The study of the prevalence of Parkinson disease. Parkinsonism and Related Disorders. 2016; 22. doi:10.1016/j.parkreldis.2015.10.023.
15. Blackett, H., Walker, R., & Wood, B. Urinary dysfunction in Parkinson's disease: A review. Parkinsonism and Related Disorders. (2009). 15(2): 81-87. doi:10.1016/j.parkreldis.2007.10.016.

16. Srivanitchapoom, P., Pandey, S., Hallett, M. Drooling in Parkinson's disease: A review. *Parkinsonism and Related Disorders*. (2014). 20(11): 1109-1118. doi:10.1016/j.parkreldis.2014.08.013.
17. Scalzo, P. L., Flores, C. R., Marques, J. R., Robini, S. C., Teixeira, A. L. Impact of changes in balance and walking capacity on the quality of life in patients with Parkinson's disease. *Arquivos de Neuro-Psiquiatria*. 2012; 70(2): 119-124. doi:10.1590/s0004-282x2012000200009.
18. Yousefi, B., Tadibi, V., Khoei, A. F., & Montazeri, A. Exercise therapy, quality of life, and activities of daily living in patients with Parkinson disease: a small scale quasi-randomised trial. *Trials*. 2009; 10(1). doi:10.1186/1745-6215-10-67.
19. Perez-Lloret, S., Negre-Pages, L., Damier, P., Delval, A., Derkinderen, P., Destée, A. Rascol, O. Prevalence, Determinants, and Effect on Quality of Life of Freezing of Gait in Parkinson Disease. *JAMA Neurology*. 2014; 71(7): 884. doi:10.1001/jamaneurol.2014.753.
20. Hechtner, M. C., Vogt, T., Zöllner, Y., Schröder, S., Sauer, J. B., Binder, H. Mikolajczyk, R. Quality of life in Parkinson's disease patients with motor fluctuations and dyskinesias in five European countries. *Parkinsonism and Related Disorders*. (2014). 20(9): 969-974. doi:10.1016/j.parkreldis.2014.06.001.
21. Santos-García, D., & Fuente-Fernández, R. D. Factors contributing to caregivers' stress and burden in Parkinson's disease. *Acta Neurologica Scandinavica*. 2014; 131(4): 203-210. doi:10.1111/ane.12305.
22. Maffoni, M., Giardini, A., Pierobon, A., Ferrazzoli, D., Frazzitta, G. Stigma Experienced by Parkinson's disease Patients: A Descriptive Review of Qualitative Studies. *Parkinson's disease*. 2017; 1-7. doi:10.1155/2017/7203259.

23. Sunvisson, H., & Ekman, S. Environmental influences on the experiences of people with Parkinson's disease. *Nursing Inquiry*. 2001; 8(1): 41-50. doi:10.1046/j.1440-1800.2001.00089.x.
24. Lokk, J., & Delbari, A. Clinical aspects of palliative care in advanced Parkinson's disease. *BMC Palliative Care*. 2012; 11(1). doi:10.1186/1472-684x-11-20.
25. Merello, M. Sialorrhoea and Drooling in Patients with Parkinson's disease. *Drugs and Aging*. 2008; 25(12): 1007-1019. doi:10.2165/0002512-200825120-00003.
26. Leibner, J., Ramjit, A., Sedig, L., Dai, Y., Wu, S. S., Jacobson, C., Fernandez, H. H. The impact of and the factors associated with drooling in Parkinson's disease. *Parkinsonism and Related Disorders*. 2010; 16(7): 475-477. doi:10.1016/j.parkreldis.2009.12.003.
27. Damian, A., Adler, C. H., Hentz, J. G., Shill, H. A., Caviness, J. N., Sabbagh, M. N., Driver-Dunckley, E. Autonomic function, as self-reported on the SCOPA-autonomic questionnaire, is normal in essential tremor but not in Parkinson's disease. *Parkinsonism and Related Disorders*. 2012; 18(10): 1089-1093. doi:10.1016/j.parkreldis.2012.06.008.
28. Sitek, E. J., Sołtan, W., Wieczorek, D., Robowski, P., Sławek, J. Self-awareness of memory function in Parkinson's disease in relation to mood and symptom severity. *Aging and Mental Health*. 2011; 15(2): 150-156. doi:10.1080/13607863.2010.508773.
29. Karakis, I., Cole, A. J., Montouris, G. D., Luciano, M. S., Meador, K. J., & Piperidou, C. Caregiver Burden in Epilepsy: Determinants and Impact. *Epilepsy Research and Treatment*. 2014; 1-9. doi:10.1155/2014/808421.
30. Werner, P., Mittelman, M. S., Goldstein, D., & Heinik, J. Family Stigma and Caregiver Burden in Alzheimer's disease. *The Gerontologist*. 2011; 52(1): 89-97. doi:10.1093/geront/gnr117.

387 **Table: 1 Patients' characteristics (n=122)**

Parameters	n	%
Hoehn and Yahr stage:		
1	7	5.7
1.5	16	13.1
2	38	31.1
2.5	36	29.5
3	19	15.5
4	4	3.2
5	2	1.6
Schwab and England activities of daily living scale		
80%- Completely independent, Conscious of difficulty and slowness	22	18.8
70% -Not completely independent	75	60.8
60% -Some dependency	25	20.4
Medications		
Levodopa	22	18
Levodopa + other Parkinson drugs	96	78.6
No drugs for Parkinson	4	32.4
Gender ratio		
Male: Female	69:53	56.5:43.5
	Mean	SD
Age in years	58.1	5.2
Disease duration in years	10.6	8.4
UPDRS score	72.8	30.2

388

389

390 **Table: 2 Care givers’ characteristics (n=130)**

Parameters	n	%
Gender ratio		
Male: Female	43:87	29.2:69.8
Little or no burden	17	13.1
Mild burden	25	19.2
Moderate burden	56	43.1
Severe burden	32	24.6
	Mean	SD
Age in years	45.1	10.2
Years dedicated as caregiver	7.2	6.4
Number of days providing care in a week	6.2	1.2

392 **Table: 3 Clinical features that significantly affected the quality of life scores**

Clinical features experienced by the participants		Mean of PDQ-39 summary index scores (SD)	p value
Non-Motor Aspects of			
Experiences of Daily Living			
Hallucinations and psychosis		45 (19.2)	0.005
Depressed mood		39 (18.6)	0.04
Urinary problems		33 (17.4)	0.02
Motor Aspects of Experiences			
of Daily Living			
Saliva and Drooling		43 (16.8)	0.003
Walking And Balance		36 (15.9)	0.05
Dressing		34 (18.2)	0.04
Getting out of bed, a car, or a deep chair		41 (17.1)	0.04
Motor Examination			
Gait		39 (19.3)	0.02
Motor Complications			
Dyskinesia		39 (19.4)	0.04
p value>0.05			

393

394

395

396

397

398 **Table: 4 PDQ-39 domains scores significantly affected caregivers’ burden scores**

Mean PDQ-39 domains scores (SD)	Mean of ZBI scores (SD)	p value
Mobility- 32 (15.4)	55 (19.2)	0.05
Activities of daily living- 19 (8.1)	39 (18.6)	0.04
Emotional wellbeing- 22 (10.3)	61 (17.4)	0.002
Stigma- 15 (7.5)	66 (16.8)	0.003

399 p value>0.05

400

401

402 **Table 5: Quality of life correlates with clinical features and care givers’ burden**

	Hallucinations and psychosis	Saliva and Drooling	Gait	Dyskinesia	Stigma					ZBI score
hallucinatio ns and psychosis	1									
Saliva and Drooling	0.28	1								
Gait	0.54	0.45	1							
Dyskinesia	0.42	0.44	0.41*	1						
Stigma	0.62*	0.60*	0.48	0.52*	1					
Emotional wellbeing	0.52*	0.58*	0.35	0.50*	0.40	1				
UPDRS score	0.40	0.42	0.40	0.37	0.31	0.33	1			
PDQ-39 score	0.38	0.45	0.28	0.30	0.34	0.36	0.68**	1		
ZBI score	0.43	0.44	0.37	0.35	0.63*	0.58*	0.41	0.76**	1	

403 * p <0.05, ** p<.005

404

405